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ABSTRACT
The purpose of our study was to test the hypothesis that 5-hy-
droxytryptamine (5-HT)1A receptor agonists counteract morphine-
induced respiratory depression. Studies were conducted in anes-
thetized rats, and respiratory activity was monitored with
diaphragm electromyography. Morphine was administered i.v. in
doses that produce apnea. Once apnea was established, i.v.
administration of the 5-HT1A receptor agonist drug 8-hydroxy-2-
(di-n-propylamino)tetralin (8-OH-DPAT) at 10 or 100 mg/kg re-
stored normal breathing in each animal (n 5 24). This antagonistic
effect of 8-OH-DPAT on morphine-induced respiratory depression
was observed in both spontaneously breathing and artificially
ventilated animals. Results obtained with 8-OH-DPAT were mim-
icked by buspirone (50 mg/kg i.v.), another 5-HT1A receptor ago-
nist drug. Pretreatment with 4-(29-methoxyphenyl)-1-[29[N-(29-
pyridinyl]-p-iodo-benzamido]ethyl]piperazine, an antagonist of
5-HT1A receptors, prevented 8-OH-DPAT from counteracting
morphine-induced apnea. These results indicate that activation of
central nervous system 5-HT1A receptors is an effective way of
reversing morphine-induced respiratory depression. Most impor-
tant, this is the third model of disturbed respiratory function in
which drugs that stimulate 5-HT1A receptors have been shown to
restore breathing to near-normal levels.
The brain serotonergic system has been implicated in the
control and/or modulation of respiratory function in a num-
ber of studies. These data have been discussed in several
review articles (e.g., Bianchi et al., 1995; McCrimmon et al.,
1995) but no clear picture emerges as to whether the seroto-
nergic system, specifically 5-hydroxytryptamine (5-HT)1A re-
ceptor activation, enhances or diminishes respiratory func-
tion. This issue can be highlighted by focusing on two
published findings. One is the report by Garner et al. (1989)
demonstrating that buspirone, a drug with 5-HT1A receptor
agonist properties (Taylor, 1988), stimulates respiratory out-
put primarily by increasing tidal volume when administered
to anesthetized and unanesthetized decerebrate cats. The
second is the report by Lalley et al. (1994a) demonstrating
that 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT),
another 5-HT1A receptor agonist drug (Middlemiss and
Fozard, 1983), inhibits respiratory output culminating in
apnea when administered to anesthetized cats.
We became interested in this problem because of the find-
ings of Lalley et al. (1994b) and Wilken et al. (1997). They
reported that 8-OH-DPAT and buspirone counteract respira-
tory disturbances (i.e., apneustic breathing) produced by hyp-
oxia, pentobarbital, and antagonists of the N-methyl-D-as-
partate receptor complex, specifically MK-801 (dizocilpine)
and ketamine, in anesthetized cats. In addition, buspirone
was found to reverse apneustic breathing in a pediatric pa-
tient after an operation to remove an astrocytoma located in
the pons and medulla (Wilken et al., 1997). Consistent with
an anti-apneustic effect of buspirone is the recent finding of
Richter et al. (1999) demonstrating that microinjection of
8-OH-DPAT into the pre-Bötzinger area of the ventrolateral
medulla will counteract hypoxia-induced apneustic breath-
ing in cats (Fig. 7 in Richter et al., 1999). In contrast, and in
the same report, these investigators report that 5-HT-in-
duced activation of 5-HT1A receptors contributes to hypoxia-
evoked respiratory depression.
In our preliminary studies using the rat as the experimen-
tal animal model, we have found that 8-OH-DPAT and bu-
spirone exert only positive effects on disturbances in respi-
ratory function; that is, 8-OH-DPAT counteracted apnea
produced by dizocilpine (Sahibzada et al., 1999), and 8-OH-
DPAT and buspirone restored breathing to normal levels in
animals subjected to spinal cord injury (Teng et al., 1999). To
further delineate the respiratory conditions under which
5-HT1A receptor activation may be of benefit or detriment to
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the organism, we examined the response to agonists of this
receptor on another model of disturbed respiratory function:
morphine-induced respiratory arrest produced in the rat.
Our findings indicate that activation of 5-HT1A receptors
restores breathing in rats with morphine-induced apnea.
Materials and Methods
General Procedures. Results were obtained with the use of 36
Sprague-Dawley adult male rats (Taconic, Germantown, NY) weigh-
ing 270 to 420 g. Anesthesia was instituted with a 3 ml/kg i.p.
injection of a cocktail containing urethane (800 mg) and a-chloralose
(60 mg) dissolved in 3 ml of 0.9% saline. The trachea was cannulated
to provide access to the airway and for instituting artificial respira-
tion when necessary. The left carotid artery was cannulated for blood
pressure recording and for calculating the heart rate from the blood
pressure trace. The right jugular and right femoral veins were can-
nulated for administration of drugs via the i.v. route. Blood pressure
was recorded using a bridge amplifier connected to a MacLab (ADI
Instruments, Milford, MA) data acquisition system. Rectal temper-
ature was monitored and maintained at 37 6 1°C with an infrared
heating lamp.
The endpoint used to detect a respiratory effect of the drugs
studied was diaphragmatic electromyogram activity. The diaphragm
electromyogram (dEMG) was obtained by making an incision below
the chest cavity and inserting a hooked bipolar platinum-iridium
electrode to the right half of the costal diaphragm. The electrode was
coupled to a p511 AC preamplifier (Grass Instruments, Quincy, MA).
The output signal of the amplifier was fed into an audiometer and
displayed on a storage oscilloscope and computer monitor. Data were
stored on computer (Apple Macintosh PowerPC connected to Ma-
cLab) for later viewing and analysis. The dEMG signal and the
software-generated integration (iEMG) of the raw signal using a
100-ms time window were continuously recorded and stored for
off-line analysis. Due to the low respiration rates in the present
study, integration at a 100-ms time constant did not change the
representation of the signal from that at a lower time constant (e.g.,
10 or 20 ms).
The cervical vagus nerves were cut bilaterally in 12 of 24 animals
used to determine the effect of 8-OH-DPAT on morphine-induced
respiratory depression. The remaining 12 animals were not vagoto-
mized. An additional 12 animals used for other studies were left with
vagi intact. The purpose of performing vagotomy was to qualitatively
assess whether peripheral receptors located in the lungs (J recep-
tors), which send afferents through the vagus, played an important
role in morphine-induced respiratory depression under our experi-
mental conditions. Willette and Sapru (1982) reported that a signif-
icant portion of the effect of morphine on respiration in the rat is due
to a peripheral action involving J receptors. Although the majority of
animals were studied in a state of spontaneous breathing, some
animals were studied under a condition of artificial respiration when
receiving morphine. The purpose for this was to maintain arterial
blood gases and pH constant. These animals were continuously ar-
tificially respired with room air by a volume ventilator (Harvard
Apparatus, South Natick, MA). All animals were ventilated on en-
tering into apnea. The respirator frequency setting was adjusted to
approximate each animal’s intrinsic respiratory rate as determined
by the dEMG signal. Occasionally, ventilation at the intrinsic rate
was found to decrease the dEMG signal strength; when this oc-
curred, the ventilator rate was reduced slightly (usually no greater
than 5 breaths/min) to increase the amplitude of the dEMG signal.
Respiratory frequency observed in the anesthetized animals used for
this study, although slower than those reported in the conscious rat
(Baker et al., 1979), were similar to those reported in other studies
using an anesthetized animal preparation (El-Bohy et al., 1998).
Experimental Protocols. In the study designed to test the effect
of 8-OH-DPAT on morphine-induced respiratory depression (i.e., ap-
nea) in spontaneously breathing animals, four groups of six animals
per group were evaluated. One group had their vagus nerves left
intact and received 10 mg/kg i.v. 8-OH-DPAT after morphine over-
dose. A second group underwent bilateral cervical vagotomy and
received 10 mg/kg i.v. 8-OH-DPAT after morphine overdose. Groups
3 and 4 both received 100 mg/kg i.v. 8-OH-DPAT after morphine
overdose, and one group had their vagus nerves left intact and the
other group underwent bilateral cervical vagotomy. These two doses
of 8-OH-DPAT were chosen because they approximate the two dose
ranges of 8-OH-DPAT that Lalley et al. (1994a) described as exhib-
iting distinctly different effects on respiratory activity in anesthe-
tized cats. The 10 mg/kg i.v. dose fits in the dose range that shortens
inspiratory duration and increases respiratory rate without directly
affecting inspiratory drive in the cat. The 100 mg/kg i.v. dose approx-
imates the range of doses that directly abolish all inspiratory drive in
the cat.
Stable baseline measurements of dEMG activity and arterial blood
pressure were obtained for a 10-min period before the experiment
was initiated. Next, for the majority of the experiments, i.v. mor-
phine injections were administered using several different dosing
regimens, with the goal of producing a stable degree of apnea. Mor-
phine was administered using a constant i.v. infusion pump, and
each dose was delivered over 24 to 36 s depending on the weight of
the animal (see Study Drugs). Morphine was administered in doses
of 4 mg/kg (n 5 3), 6 mg/kg (n 5 19), or 15 mg/kg (n 5 2) repeated
once every 2 to 5 min until apnea was produced. No significant
differences in total morphine dose administered were seen between
any of the four treatment groups receiving 8-OH-DPAT. The mean
dose of morphine administered was 21.3 6 2.1 mg/kg for all animals.
Apnea was initially judged to occur when no respiratory activity was
detected for longer than 20 s. During this initial apnea, blood pres-
sure was observed to fall precipitously, and this necessitated placing
animals on a ventilator. Animals were artificially respired for at
least 1 min to restore blood pressure and blood gasses before being
tested for evidence of a stable apnea. A stable apnea was considered
to be present if removal of the animal from the ventilator for 20 to
30 s, during which time CO2 would accumulate, did not restore
dEMG activity. If spontaneous breathing returned with removal of
the animal from the ventilator, another morphine bolus dose was
administered, and this cycle was repeated until suspension of arti-
ficial respiration was ineffective in restoring respiratory activity. At
this point, animals were artificially ventilated continuously, and i.v.
8-OH-DPAT in doses of either 10 mg/kg (n 5 12) or 100 mg/kg (n 5 12)
were administered to attempt to restore respiratory activity. Artifi-
cial ventilation was removed when diaphragmatic activity was ob-
served to return; animals were then allowed to breathe spontane-
ously and were followed for 15 to 20 min after the 8-OH-DPAT
infusion.
The protocol just described was used in spontaneously breathing
animals. In an additional group of rats (n 5 5), animals were placed
on artificial respiration at the outset of the experiment, and artificial
respiration was maintained for the duration of the study. Stable
baseline values for amplitude and frequency of dEMG, the iEMG,
and the arterial blood pressure were established over a 10-min
observation period. Morphine in i.v. infusion doses delivered over 24
to 36 s at 4 mg/kg was administered at 2- to 5-min intervals until the
dEMG signal was abolished. One animal received a single bolus dose
of 12 mg/kg morphine, which produced apnea. In all cases, a waiting
period of 2 min was used to ensure loss of the signal; at this point,
8-OH-DPAT in an i.v. dose of 10 mg/kg was administered. The end-
point of the 8-OH-DPAT effect was restoration of the dEMG signal.
In these studies, two of the five rats received buspirone in an i.v. dose
of 50 mg/kg instead of 8-OH-DPAT.
Other studies that we performed investigated the: 1) effects of
8-OH-DPAT alone on cardiorespiratory activity, 2) pretreatment
with an antagonist of 5-HT1A receptors (the antagonist was also
administered i.v. using a constant infusion pump such that a single
dose was administered over 24–36 s) to determine whether the effect
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of 8-OH-DPAT on morphine-induced respiratory depression could be
prevented, and 3) effects of an antagonist of 5-HT1A receptors on
cardiorespiratory activity. The protocols for these latter studies are
described in Results. All experiments were carried out in accordance
with the National Institutes of Health guidelines for the use of
animals in research.
Data Analysis. All respiratory indices (dEMG, iEMG, and arte-
rial blood pressure) were continuously recorded and stored on video-
tape and on computer. Data were analyzed off-line with an Apple
Macintosh PowerPC using the MacLab (ADI Instruments) data ac-
quisition system. Control or baseline values were obtained by aver-
aging values during a 10-s period. Peak effects of each drug were
obtained by noting the maximum change in cardiorespiratory activ-
ity that occurred at 30-s and 1-, 2-, 3-, 4-, 5-, and 10-min time points
after the i.v. infusion of drug had ended. Values obtained at these
time points were taken by averaging data during a period of 10 s. The
EMG signal that was used for our calculation was obtained from the
peak signal of the integrated EMG rather than the raw dEMG signal
due to an occasional large amplitude single spike occurring in the
raw signal, which would be unduly weighted by the data acquisition
software analysis program. Values are given as means 6 S.E. Anal-
ysis of the change in iEMG amplitude from baseline (percent change)
was accomplished using a Wilcoxon signed rank test. All other data
were statistically analyzed using a one-way repeated measures
ANOVA. Differences between groups were analyzed using a Student-
Newman-Keuls test and were considered significant if P , .05.
Study Drugs. Urethane and a-chloralose were purchased from
Sigma Chemical Co. (St. Louis, MO). Urethane (800 mg) and a-chlo-
ralose (60 mg) were dissolved in 3 ml of 0.9% saline. Morphine
sulfate was purchased from Elkins-Sinn (a division of A. H. Robins
Co., Richmond, VA) and dissolved in 0.9% saline as a 15 mg/ml
solution. The 5-HT1A receptor agonist drugs 8-OH-DPAT and buspi-
rone were purchased from Research Biochemicals Inc. (Natick, MA).
Both drugs were dissolved in 0.9% saline and administered in doses
of 10 or 100 mg/kg for 8-OH-DPAT and 50 mg/kg for buspirone. These
doses were selected based on the previous reports that describe
5-HT1A agonist-induced reversal of apneustic breathing (Lalley et
al., 1994a; Wilken et al., 1997). The 5-HT1A receptor antagonist
4-(29-methoxyphenyl)-1-[29[N-(29-pyridinyl]-p-iodo-benzamido]eth-
yl]piperazine (p-MPPI) was also purchased from Research Biochemi-
cals Inc. and was dissolved in 0.9% saline heated to 50–60°C to
facilitate complete dissolution of the drug. The dose of administered
p-MPPI was either 20 or 40 mg/kg. This produced a p-MPPI/8-OH-
DPAT ratio, on a mg/kg basis, similar to previous reports that dem-
onstrated p-MPPI antagonism of 8-OH-DPAT effects (Allen et al.,
1997; Shaikh et al., 1997; Wolff and Leander, 1997). All drugs, with
the exception of the anesthetic agents (which were administered
i.p.), were administered via polyethylene tubing connected to a 5-ml
syringe driven by a Sage infusion pump. All i.v. drugs were infused
at a constant rate of 0.69 ml/min. Drugs were prepared such that 1
ml of drug solution contained the dose necessary to achieve the
desired dose in a 1.0-kg animal. Thus, the duration of drug infusion
was the principal method used to achieve appropriate final dose in
each animal and, depending on the animal’s weight, varied between
24 and 36 s.
Results
Two 5-HT1A receptor agonist drugs, 8-OH-DPAT and bu-
spirone, were tested separately to determine their ability to
reverse morphine-induced respiratory depression. To assess
the effects of 8-OH-DPAT and buspirone on morphine-in-
duced respiratory depression, we first examined the effect of
morphine on cardiorespiratory function.
Effect of Morphine on Respiration in Spontaneously
Breathing Rats. Morphine was administered i.v. to 24 spon-
taneously breathing animals using the dosing regimens de-
scribed earlier; the effects are given in Table 1. Half of the
animals underwent bilateral cervical vagotomy. A represen-
tative experiment of the effect of morphine in a vagus nerve-
intact animal appears in Fig. 1, A and B. The endpoint of a
morphine effect with each dosing regimen was the occurrence
of apnea. The dose of morphine to produce apnea did not
differ significantly between the vagus nerve-intact and the
vagotomized animals (P . .05). The usual respiratory effect
of morphine before the onset of apnea was a decrease in
respiratory frequency (67 6 3 to 31 6 6 breaths/min, P , .05,
for vagus nerve-intact animals; 51 6 2 to 27 6 6 breaths/min,
P , .05, for vagotomized animals) and a decrease in the
iEMG (in arbitrary units: 101 6 15 to 75 6 12, P , .05, for
vagus nerve-intact animals; 110 6 14 to 80 6 12, P , .05, for
vagotomized animals). With the occurrence of apnea, all an-
imals were placed on artificial respiration before the admin-
istration of 8-OH-DPAT (see Materials and Methods). Values
for mean arterial pressure and heart rate were obtained and
tabulated just before the administration of 8-OH-DPAT (Ta-
ble 1). Both vagus nerve-intact and vagotomized animals
exhibited a fall in mean arterial pressure after morphine
administration, whereas only the vagus nerve-intact animals
exhibited a statistically significant decrease in heart rate
after morphine administration.
Effects of 8-OH-DPAT on Morphine-Induced Respi-
ratory Depression in Spontaneously Breathing Rats.
The 24 animals described earlier were placed on artificial
respiration once life-threatening respiratory depression de-
veloped subsequent to morphine administration (see Materi-
als and Methods). 8-OH-DPAT was administered i.v. in doses
of either 10 mg/kg (n 5 12) or 100 mg/kg (n 5 12) over a period
of 24 to 36 s. We found in our study that the 10 and 100 mg/kg
i.v. doses exerted the same effect, namely, reversal of mor-
phine-induced apnea (Table 1 and Fig. 1, C–E). This occurred
regardless of the status of the animal’s vagus nerves. The
time interval between the occurrence of morphine-induced
apnea and the administration of 8-OH-DPAT was 6.3 6 0.5
min, during which the animal was continuously ventilated.
Reversal of morphine-induced apnea occurred in half of the
animals even before the continuous infusion of 8-OH-DPAT
had been completed, and for all animals, it occurred within 2
min of completion of infusion. The time of the peak effect of
8-OH-DPAT on respiratory rate was similar in all animals
and averaged 2.6 6 0.3 min after the completion of i.v.
infusion. Generally, animals were followed for 15 to 20 min
after the administration of 8-OH-DPAT, and within this time
frame, reversal of morphine-induced apnea was still present
in most animals. No important differences were noted be-
tween the effectiveness of 10 and 100 mg/kg doses of 8-OH-
DPAT. We also tested the effectiveness of 1 mg/kg 8-OH-
DPAT in four animals (data not shown) and found that only
one of four animals exhibited a reversal of morphine-induced
apnea when 1 mg/kg 8-OH-DPAT was administered i.v.. We
also noted that the recovery of respiration after 8-OH-DPAT
infusion was more robust once the respirator was switched
off (see, e.g., Figs. 1D and 4E). This increase in dEMG am-
plitude may have been due to the absence of a respiratory
phase conflict between the ventilator and the spontaneous
respiratory drive of the animal.
The efficacy of 8-OH-DPAT to restore morphine-induced
cardiorespiratory depression to normal can be extracted from
data in Table 1; 8-OH-DPAT normalized the amplitude of the
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iEMG signal. However, even though respiratory rate was
close to baseline values, respiratory rate remained signifi-
cantly below the baseline respiratory rates before morphine
administration. A somewhat similar picture can be seen with
the mean arterial blood pressure values. Morphine produced
a decrease in mean arterial blood pressure and the adminis-
tration of 8-OH-DPAT partially restored mean arterial pres-
sure toward normal values in all groups. Heart rate values
remained unchanged by the administration of 8-OH-DPAT. A
representative experiment showing reversal of morphine-in-
duced apnea by 8-OH-DPAT appears in Fig. 1.
Effects of 8-OH-DPAT Per Se on Respiration in Spon-
taneously Breathing Rats. 8-OH-DPAT doses that were
found to be effective in reversing morphine-induced apnea
were administered to three animals that had not received
morphine to examine the cardiorespiratory effects of this
5-HT1A receptor agonist drug. The baseline respiratory rate,
mean arterial blood pressure, and heart rate of animals re-
ceiving 8-OH-DPAT were 62 6 4 breaths/min, 96 6 7 mm Hg,
and 429 6 19 beats/min, respectively. 8-OH-DPAT adminis-
tered as either the 10 mg/kg i.v. dose or the 100 mg/kg i.v. dose
had no significant effect (P . .05) on respiratory rate, iEMG
amplitude, mean arterial blood pressure, or heart rate (10
mg/kg: 61 6 5 breaths/min, 93 6 9 mm Hg, and 405 6 8
beats/min, respectively; 100 mg/kg: 61 6 4 breaths/min, 86 6
12 mm Hg, 374 6 24 beats/min, respectively). 8-OH-DPAT
values were obtained 1 to 2 min after drug administration.
This time point coincides with the time at which 8-OH-DPAT
was found to exert its peak effect to reverse morphine-in-
duced apnea.
Effects of 8-OH-DPAT on Morphine-Induced Apnea
in Artificially Respired Rats. To further rule out CO2
accumulation as a factor in reversing morphine-induced ap-
nea, we performed three experiments similar to those de-
scribed earlier except the animals were artificially ventilated
throughout the experiment. In all three animals, a single i.v.
dose of 4 mg/kg (n 5 2) or three i.v. doses of 4 mg/kg (n 5 1)
morphine produced apnea as reflected by disappearance of
the EMG signal (Fig. 2B). Within 2 min after the occurrence
of apnea, the i.v. administration of 10 mg/kg 8-OH-DPAT
restored breathing to normal in all three animals (i.e., EMG
signal was restored and the amplitude of the signal was
similar to the amplitude during the control period; Fig. 2C).
Restoration occurred within 1 min of 8-OH-DPAT adminis-
tration and was maintained until the end of the experiment.
The tabulated data from these three experiments appear in
Table 1 and indicate that values for respiratory frequency
and iEMG amplitude after 8-OH-DPAT were not statistically
different (P . .05) from the corresponding values obtained
before morphine administration. Also, mean blood pressure
and heart rate were well maintained in these artificially
ventilated animals throughout the duration of the experi-
ment.
Effects of Buspirone on Morphine-Induced Apnea in
Artificially Ventilated Rats. The effects of the 5-HT1A
receptor agonist drug buspirone on morphine-induced apnea
were studied in two animals placed on artificial respiration.
Apnea was produced by administering three (n 5 1) or five
(n 5 1) i.v. doses of 4 mg/kg morphine. Buspirone, adminis-
tered i.v. in a dose of 50 mg/kg over 24 to 28 s, reversed
morphine-induced apnea in both cases, and this reversal
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experiment illustrating the ability of buspirone to counteract
morphine-induced apnea appears in Fig. 3. In contrast to the
persistent effect of 8-OH-DPAT, the effect of buspirone began
to diminish within 5 min after administration in both ani-
mals (Fig. 3D). However, repeat administration of 50 mg/kg
i.v. buspirone reestablished the antagonism of morphine-
induced respiratory depression in both experiments.
Effects of p-MPPI Pretreatment on Capacity of 8-OH-
DPAT to Reverse Morphine-Induced Respiratory De-
pression. Four experiments were performed in spontane-
ously breathing animals. The protocol used was as follows:
morphine was first administered using the 6 mg/kg bolus
dose regimen described in Materials and Methods until a
stable apnea was present. Next, p-MPPI, an antagonist of
5-HT1A receptors (Kung et al., 1994), was administered i.v. at
a dose of 40 mg/kg. This was followed by the i.v. administra-
tion of 8-OH-DPAT in a dose of 10 mg/kg. In three of the four
experiments, 10 mg/kg 8-OH-DPAT i.v. failed to counteract
Fig. 1. Reversal of morphine-induced apnea by 10 mg/kg 8-OH-DPAT i.v. in a spontaneously breathing vagi-intact rat. A, control traces of blood
pressure (BP), dEMG, and iEMG. B, trace obtained 2 min and 20 s after the third i.v. dose of 6 mg/kg morphine. Artificial respiration was instituted
at the time of the onset of apnea. The animal was briefly removed from the ventilator as shown to determine whether CO2 accumulation would reverse
apnea and restore respiratory rhythm (see Materials and Methods). Apnea was not reversed after 15 s off the ventilator, pressure was observed to drop
markedly, and the animal was put back on artificial respiration (not shown). C, trace obtained at the conclusion of i.v. administered 8-OH-DPAT. Note
recovery of breathing within 10 s after administration of the 5-HT1A agonist. D, the animal was taken off the ventilator as indicated by the notation
“Off Resp” and allowed to breathe spontaneously for the duration of the experiment. E, cardiorespiratory traces obtained 10 min after 8-OH-DPAT
administration demonstrating the continued effect of 8-OH-DPAT-induced respiratory recovery. Respiration was maintained at this level for the
duration of the experiment (25 min). Horizontal lines at the bottom of each panel represent the time in minutes and seconds from the beginning of
the experimental recording. Each panel represents a 20-s record of the above indices.
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morphine-induced apnea in animals pretreated with p-MPPI
(note that the time interval between the administration of
p-MPPI and 8-OH-DPAT was 5.2 6 0.6 min). This contrasts
with 12 of 12 animals in which 10 mg/kg 8-OH-DPAT i.v.
counteracted morphine-induced apnea in the absence of p-
MPPI pretreatment (Table 1). One of the four animals did
show reversal of morphine-induced apnea with the 10 mg/kg
i.v. dose of 8-OH-DPAT. In the three animals in which p-
MPPI was administered and 10 mg/kg8-OH-DPAT i.v. was
found to be ineffective, subsequent administration of a 100
mg/kg dose of 8-OH-DPAT did reverse morphine-induced ap-
nea (Fig. 4E). The 100 mg/kg i.v. dose of 8-OH-DPAT was
administered 9.8 6 0.9 min after the 10 mg/kg i.v. dose of
8-OH-DPAT had been administered.
Effect of p-MPPI in Spontaneously Breathing Ani-
mals. The respiratory effects of p-MPPI alone were studied
in three animals. The dose of 40 mg/kg p-MPPI was admin-
istered i.v., and data were obtained at 5 min after this dose
was administered. p-MPPI per se had no important effects on
cardiorespiratory function. Baseline values for respiratory
frequency, mean arterial blood pressure, and heart rate were
72 6 6 breaths/min, 94 6 1 mm Hg, and 407 6 42 beats/min,
respectively. These values were not significantly altered
within 5 min after the drug was administered (67 6 4
breaths/min, 100 6 3 mm Hg, and 420 6 38 beats/min). The
percentage change in amplitude of iEMG was 16 6 3%.
Thus, p-MPPI alone had no significant effect on cardiorespi-
ratory function.
In general, we noted that the recovery of respiration after
8-OH-DPAT infusion was more robust once the respirator
was switched off (see, e.g., Figs. 1D and 4E). This increase in
dEMG amplitude may have been due to the absence of a
respiratory phase conflict between the ventilator and the
spontaneous respiratory drive of the animal.
Discussion
The purpose of our study was to address the question of
whether activation of 5-HT1A receptors results in an im-
provement or deterioration of respiratory function. To an-
swer this question, we evaluated the effects of 5-HT1A recep-
tor agonists 8-OH-DPAT and buspirone on drug-induced
respiratory depression using a model of morphine overdose in
the anesthetized rat. The 5-HT1A receptor agonist drug
8-OH-DPAT administered i.v. counteracted apnea produced
by i.v. morphine. Although the bulk of our data were obtained
with 8-OH-DPAT, we also observed that buspirone, a partial
agonist at 5-HT1A receptors (Taylor, 1988), also reversed
apnea. Evidence that the positive effect of 8-OH-DPAT on
depressed respiratory function was due to an action to stim-
ulate 5-HT1A receptors was obtained using p-MPPI, a selec-
tive antagonist of the 5-HT1A receptor (Kung et al., 1994).
Pretreatment of animals with p-MPPI i.v. prevented the 10
mg/kg i.v. dose of 8-OH-DPAT from counteracting apnea pro-
duced by i.v. morphine. Not only did we find that 5-HT1A
receptor agonists reverse apnea produced by morphine, but
also our most recent data indicate that 8-OH-DPAT admin-
istered i.v. to rats reverses apnea caused by the antagonist of
the N-methyl-D-aspartate receptor complex, dizocilpine (Sa-
hibzada et al., 1999). In addition, we found that i.p. admin-
Fig. 2. Reversal of morphine-in-
duced apnea by 10 mg/kg 8-OH-
DPAT i.v. in an artificially respired
vagi-intact rat. A, control traces for
blood pressure (BP), dEMG, and
iEMG. B, traces obtained 4 min af-
ter 4 mg/kg morphine i.v. produced
apnea. C, traces obtained 1 min af-
ter 10 mg/kg 8-OH-DPAT i.v. was
administered. Note the recovery of
dEMG and iEMG signals. D, traces
obtained 31 min after 8-OH-DPAT
administration. Horizontal lines at
the bottom of each panel represent
the time in minutes and seconds
from the beginning of the experi-
mental recording. Each panel rep-
resents a 20-s record of the above
indices.
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istration of either 8-OH-DPAT or buspirone will restore
breathing to normal in rats with spinal cord injury and
associated disturbances in respiratory function (Teng et al.,
1999).
Our data are consistent with the view that the adminis-
tration of drugs that activate 5-HT1A receptors are of poten-
tial benefit in situations where life-threatening respiratory
depression is present. Our findings fit with those of others
who have studied 5-HT1A agonists, specifically buspirone,
and found a stimulatory respiratory effect of this compound
in anesthetized and conscious experimental animals and hu-
mans (Garner et al., 1989; Mendelson et al., 1990, 1991).
Garner et al. (1989) administered buspirone i.v. to anesthe-
tized cats and reported that a dose of 0.32 mg/kg increased
respiratory rate, tidal phrenic activity, and minute phrenic
activity. Additionally, buspirone decreased the apneic
threshold (determined by reduction in pCO2 levels until
breathing ceased) and shifted the CO2 response curve to the
left of the control CO2 response curve. Mendelson et al.
(1990) administered buspirone to conscious rats in doses of
10 and 20 mg/kg i.p. and monitored respiration by the “baro-
metric technique.” Both doses of buspirone were reported to
increase respiratory rate, tidal volume, and minute ventila-
tion. This group of investigators went on to study buspirone
in humans with obstructive sleep apnea (Mendelson et al.,
1991). They reported that buspirone decreased the number of
apneas by one third in five patients.
Although Garner et al. (1989) and Mendelson et al. (1990)
observed pronounced effects of buspirone in normal breath-
ing animals, we did not observe alterations in respiration
with 8-OH-DPAT unless respiratory depression was present.
One possible explanation for this discrepancy is that our i.v.
drug doses were relatively low (i.e., 10 and 100 mg/kg for
8-OH-DPAT and 50 mg/kg for buspirone). In our most recent
study of the effect of these drugs on respiratory function of
normal conscious rats, we found that the i.p. administration
of larger doses (i.e., 250 mg/kg 8-OH-DPAT and 500 mg/kg
buspirone) does produce significant respiratory stimulation
(Teng et al., manuscript in preparation). Others have re-
ported that 8-OH-DPAT will produce hypotension in anes-
thetized rats (e.g., Fozard et al., 1987). We assume that
8-OH-DPAT was administered as a rapid i.v. infusion in the
study by Fozard et al., whereas we administered 8-OH-DPAT
as a continuous i.v. infusion such that the dose of drug was
administered over a period of 24 to 36 s. In addition, the
mean blood pressures of the rats in the study by Fozard et al.
were much higher than the mean blood pressures of our rats,
but these investigators reported that 8-OH-DPAT lowered
mean blood pressure to a range that coincided with the mean
blood pressures in our study (i.e., 80–100 mm Hg).
In contrast to the findings described previously in which
5-HT1A receptor agonists produce a stimulatory effect on
respiration and are useful in countering respiratory depres-
sion, other investigators have suggested that these drugs
produce a depressant effect on respiration. Richter et al.
(1996) provide evidence that indicate the predominant effect
of local application of 5-HT on respiratory neurons is inhibi-
tion of activity and that this response is mediated through
activation of 5-HT1A receptors. Subsequent to activation of
the 5-HT1A receptor, there is augmentation of potassium
conductances and inhibitory postsynaptic currents. In their
most recent study using phrenic nerve recordings from anes-
thetized cats (Richter et al., 1999), 8-OH-DPAT was admin-
istered i.v. or microinjected into the pre-Bötzinger complex,
Fig. 3. Reversal of morphine-in-
duced apnea by 50 mg/kg buspirone
i.v. in an artificially respired vagi-
intact rat. A, control traces for blood
pressure (BP), dEMG, and iEMG. B,
traces taken 5 min after 12 mg/kg
morphine i.v. in a single bolus dose
produced apnea. C, traces obtained 1
min after buspirone was adminis-
tered i.v. Note recovery of dEMG and
iEMG signals. D, traces obtained 5.5
min after administration of buspi-
rone. At this time, morphine-induced
respiratory depression had been re-
established. Horizontal lines at the
bottom of each panel represent the
time in minutes and seconds from
the beginning of the experimental re-
cording. Each panel represents a
20-s record of the above indices.
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an area of the ventral respiratory group that is considered to
be essential for the generation of respiratory rhythm (Smith
et al., 1991). Intravenous administration of 20 mg/kg 8-OH-
DPAT produced apnea as registered as a total absence of
neural discharge on the phrenic nerve recording. The same
was true when 8-OH-DPAT was microinjected in an amount
of 0.23 nmol unilaterally into the pre-Bötzinger complex.
Richter and colleagues (Lalley et al., 1994b; Wilken et al.,
1997; Pierrefiche et al., 1998) made the important discovery
that drugs that act as 5-HT1A receptor agonists, such as
8-OH-DPAT and buspirone, can successfully abolish one type
of respiratory disturbance, namely, apneustic breathing.
Their explanation for this beneficial effect fits with their
conclusion that 5-HT1A receptor agonists exert a depressant
effect on respiratory neurons. In their view, an apneustic
pattern of breathing can be caused by blockade of synaptic
inhibition within the pre-Bötzinger complex (Pierrefiche et
al., 1998), leading to inappropriate and sustained excitation
Fig. 4. p-MPPI (40 mg/kg i.v.) prevents restoration of respiratory activity by 10 mg/kg 8-OH-DPAT in a rat with morphine-induced apnea. A, control
traces for blood pressure (BP), dEMG, and iEMG in a spontaneously breathing vagi-intact animal. B, traces obtained 8 min after a fifth and final bolus
dose of morphine (total dose administered, 30 mg/kg) demonstrating the occurrence of apnea. Note at this time, the rat was artificially ventilated.
Removal of the rat from the ventilator for periods of 20 s was ineffective in generating respiratory activity. C, traces obtained 3 min after i.v.
administration of p-MPPI; no effect on cardiorespiratory function was observed. D, traces obtained 30 s after administration of 10 mg/kg 8-OH-DPAT
demonstrating the lack of reversal of respiratory depression at a time when this dose of 8-OH-DPAT always reversed morphine-induced apnea in the
absence of p-MPPI. Removal of artificial ventilation also failed to restore respiratory activity, and the animal was put back on the ventilator. E, traces
obtained 20 s after beginning infusion of 100 mg/kg dose of 8-OH-DPAT. This higher dose was able to restore respiration even before the complete dose
was infused, and the animal was removed from the ventilator and allowed to breathe spontaneously for the duration of the experiment with no
recurrence of apnea observed. Horizontal lines at the bottom of each panel represent the time in minutes and seconds from the beginning of the
experimental recording. A–D, a 20-s record of the above indices; E, 50-s record of the above indices.
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of respiratory neurons. The administration of a 5-HT1A re-
ceptor agonist would result in a postsynaptic inhibitory effect
on respiratory neurons due to 5-HT1A receptor-induced acti-
vation of an outward potassium current that would act to
hyperpolarize the membrane. This would counteract disinhi-
bition-induced membrane depolarization of pre-Bötzinger
neurons and restore rhythmic respiratory activity (Pier-
refiche et al., 1998).
Thus, two diametrically opposed views exist for the effect
of 5-HT1A receptor agonists on respiration: one highlighted
by our present data and the data of Garner et al. (1989) and
Mendelson et al. (1990 and 1991) indicating that these drugs
are respiratory stimulants, and the other highlighted by the
data of Richter and colleagues (Richter et al., 1996, 1999;
Pierrefiche et al., 1998) indicating that these drugs are re-
spiratory depressants. At the present time, it is not possible
to explain these contradictory findings as being due to differ-
ences in species, anesthetic regimen, or drug dose studied.
The same species and anesthetic regimen were used in two
studies yielding opposite results (Garner et al., 1989; Richter
et al., 1999). In the present study, we used the same dose
range of 8-OH-DPAT as Richter et al. (1999).
A possible explanation for why 5-HT1A receptor agonists re-
verse morphine-induced respiratory depression can be found in
data from an earlier study of Florez et al. (1972), in which an
interaction between the serotonergic system and morphine was
revealed. These investigators reported that pretreatment of
cats with p-chlorophenylalanine, an inhibitor of 5-HT synthesis,
counteracted morphine-induced depression of CO2-stimulated
respiration and reduced morphine-induced respiratory depres-
sion observed during ventilation with normal levels of inspired
CO2. Another way to inhibit the serotonergic system is by ad-
ministering 5-HT1A receptor agonists. These drugs in the dose
range used in our study have been demonstrated to stimulate
5-HT1A autoreceptors, and this effect completely inhibits the
activity of serotonergic raphe nucleus discharge (Trulson and
Arasteh, 1986; Jacobs and Azmitia, 1992; Veasey et al., 1995)
and presumably the release of serotonin at target sites inner-
vated by the raphe nuclei. Because brainstem raphe neurons
innervate respiratory centers (Lindsey et al., 1998) and because
stimulation of brainstem raphe neurons causes depression of
respiration and apnea (Lalley et al., 1997), it logically follows
that a drug such as 8-OH-DPAT would counteract respiratory
depression because it inhibits raphe neurons. Buspirone also
inhibits raphe neuron firing (Trulson and Arasteh, 1986) and
would therefore exert the same profile of effects as 8-OH-DPAT.
Evidence in support of this idea that 5-HT1A receptor agonists
exert their beneficial effects on depressed breathing by inhibit-
ing central serotonergic mechanisms are findings indicating
that 8-OH-DPAT, buspirone, and pretreatment of animals with
p-chlorophenylalanine all produce respiratory stimulation
(Florez et al., 1972; Garner et al., 1989; Mendelson et al., 1990;
Teng et al., 1999).
We propose that the beneficial respiratory effects of
5-HT1A receptor agonist drugs is due to an effect on somato-
dendritic 5-HT1A autoreceptors leading to the inhibition of
central serotonergic neuronal discharge. In contrast, Richter
et al. (1999) propose that the respiratory depressant effects of
5-HT1A receptor agonist drugs are due to an effect on
postsynaptic 5-HT1A receptors leading to hyperpolarization
of respiratory neurons. Further studies are needed to estab-
lish these proposed mechanisms and/or sites of action, and if
pursued, they may help to elucidate why both respiratory
stimulation and respiratory depression have been reported
for these drugs.
In summary, our data suggest that drugs that stimulate
5-HT1A receptors are effective in restoring disturbances in
respiratory function to normal. Data were obtained with
8-OH-DPAT and buspirone reversal of morphine-induced ap-
nea, but additional preliminary data of ours also show that
these drugs will reverse dizocilpine-induced apnea (Sa-
hibzada et al., 1999), and spinal cord injury-induced respira-
tory depression (Teng et al., 1999). Thus, the positive effect of
5-HT1A receptor agonists on disturbed respiratory function
may be a general phenomenon and not limited to morphine
overdose.
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